| Name | RG2833 |
| Description | RG2833 (RGFP109) (RGFP109), a brain-penetrant HDAC inhibitor, is with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. |
| Kinase Assay | Aconitase activities are determined by homogenization of mouse brain tissues on ice at 10% w/v in CellLytic MT Mammalian Tissue Lysis/Extraction buffer, followed by centrifugation at 800×g?for 10?min at 4°C. Tissue lysates (50?μL) are then added to 200?μL of substrate mix (50?mM Tris/HCl pH 7.4, 0.4?mM NADP, 5?mM Na citrate, 0.6?mM MgCl2, 0.1% (v/v) Triton X-100 and 1U isocitrate dehydrogenase) and the reactions are incubated at 37°C for 15?min, followed by spectrophotometric absorbance measurements every minute for 15?min at 340?nm 37°C to determine the reaction slope. Aconitase activities of mouse brain tissues are then normalized to citrate synthase activities, which are determined using a citrate synthase assay kit. |
| In vitro | In unstimulated peripheral blood mononuclear cells, RG2833 upregulates the level of the synaptic mRNA and protein in a dose-dependent manner. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (132.58 mM)
Ethanol : 10 mg/mL (29.46 mM)
|
| Keywords | RGFP-109 | RG2833 | Inhibitor | RG 2833 | HDAC | inhibit | RGFP 109 | Histone deacetylases | RG-2833 |
| Inhibitors Related | Valproic acid sodium salt | Panobinostat | Theophylline monohydrate | Sodium 4-phenylbutyrate | Vorinostat | Acefylline | Curcumin | Valproic Acid | Parthenolide | 4-Phenylbutyric acid | Theophylline | Methyl L-histidinate dihydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Autophagy Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
